连续性肾脏替代治疗患者体外循环凝血的危险因素及护理研究进展被引量：80

Influencing factors of circuit patency for continuous renal replacement therapies and contermeasures:a review

导出

摘要连续性肾脏替代治疗（continuous renal replacement therapy, CRRT）中，频繁的体外循环（管路、滤器、中心静脉导管）凝血，使得实际治疗时间缩短，实际超滤量减少，不仅降低治疗的充分性，增加患者的血液丢失，而且增加护理工作量．间接增加CRRT治疗花费。尽量避免体外循环凝血．延长体外循环装置的使用寿命是CRRT治疗的重点。体外循环凝血的影响因素包括患者凝血状态、抗凝方式和护理干预措施等。护理干预对CRRT体外循环治疗的维持起重要作用。本文将对CRRT体外循环抗凝的相关因素和护理干预措施进行综述。

作者刘翔龚德华季大玺崔俊孔凌刘云

机构地区蚌埠医学院护理学系南京军区南京总医院全军肾脏病研究所南京军区南京总医院护理部

出处《中华护理杂志》 CSCD 北大核心 2013年第4期377-379,共3页 Chinese Journal of Nursing

关键词肾替代治疗血液凝固护理 Renal Replacement Therapy Blood Coagulation Nursing Care

分类号 R473.5 [医药卫生—护理学]

作者简介刘翔：女，本科（硕士在读），E—mail：liuxiang．yzu@163．com通信作者：刘云，E-mail：njzyhlb@126.com

引文网络
相关文献

参考文献31

1Webb AR,Mythen MG,Jacobson D,et al. Maintaining blood flow in the extracorporeal circuit:haemostasis and anticoagulation[J].lntensive Care Med, 1995,21 ( 1 ) : 84-93.
2王云燕,刘晓莉,刘均敏.血液透析器出现凝血的原因分析和护理对策[J].解放军护理杂志,2006,23(5):48-49. 被引量：48
3Baldwin I. Factors affecting circuit patency and filter 'life'[J].Contrib Nephrol, 2007,156 : 178-184.
4Kleger GR, Fassler E. Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? [J].Int J Artif Organs,2010,33(3) : 139-146.
5Davies H,Morgan D,Leslie G.A regional citrate anticoagulation protocol for pre-dilutional CVVHDF: the 'Modified Alabama Protocol' [J].Aust Crit Care,2008,21 (3) : 154-165.
6Zhang Z,Hongying N.Efficacy and safety of regional citrate anticoa- gulation in critically ill patients undergoing continuous renal repla- cement therapy[J].Intensive Care Med,2012,38(1):20-28.
7Uchino S,Fealy N,Baldwin I,et al.Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration:impact on filter life and azotemic control[J].Nephron Clin Pract,2003,94(4) :C94-98.
8Hotbauer R,Moscr D,Frass M,et al.Role of contact system activation in hemodialyzer-induced thrombogenicity[J]. Kidney Int,2001,60:1972-1981.
9Polanska K,Opatrny K, Rokyta R, et al.Effect of regional citrate anticoagulation on thrombogenicity and biocompatibility during CVVHDF [J].Ren Fail,2006,28(2) : 107-118.
10张凯悦,徐斌,吴丛业,刘志红,季大玺,龚德华.局部枸橼酸联合小剂量低分子肝素抗凝在连续性肾脏替代治疗中的应用[J].肾脏病与透析肾移植杂志,2012,21(4):311-316. 被引量：31

二级参考文献58

1王瑛,乔艳红,常靖,关波.高脂血症患者血液流变学指标检测[J].中国血液流变学杂志,2004,14(3):370-371. 被引量：23
2方峻,夏凌辉,魏文宁,宋善俊.尿毒症患者凝血因子Ⅶ水平及其影响因素[J].中国实验血液学杂志,2004,12(6):730-732. 被引量：10
3Gott VL,Whiffen JD,Dutten RC.Heparin bonding colloidal graphite surfaces[J].Science 1963,142:1297-1298.
4Edmunds LH Jr.Hastings lecture.Breaking the blood-biomaterial barrier[J].ASAIO J,1995,41(4):824-830.
5Baksaas ST,Videm V,Fosse E,et al.In vitro evaluation of new surface coatings for extracorporeal circulation[J].Perfusion,1999,14(1):11-19.
6Hioki I,Nishikawa M,Onoda K,et al.A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass[J].Thromb Haemost,1998,80(3):437-442.
7Videm V,Nilsson L,Venge P,et al.Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass[J].Artif Organs,1991,15(2):90-95.
8Zwaal RF,Comfurius P,van Deenen LL.Membrane asymmetry and blood coagulation[J].Nature,1977,268(5618):358-360.
9Stammers AH,Christensen KA,Lynch J,et al.Quantitative evaluation of heparin-coated versus nonheparin-coated bypass circuits during cardiopulmonary bypass[J].J Extra Corpor Technol,1999,31(3):135-141.
10Mangoush O,Purkayastha S,Haj-Yahia S,et al.Heparin-bonded circuits versus nonheparin-bonded circuits:an evalutation of their effect on clinical coutcomes[J].Eur J Cardiothorac Surg,2007,31(6):1058-1069.